Increased macrolide resistance rate of Mycoplasma pneumoniae correlated with epidemic in Beijing, China in 2023
Authors:
Open Access
- 6 August 2024
- journal article
- research article
- Published by Frontiers Media SA in Frontiers in Microbiology
- Vol. 15, 1449511
Abstract
We collected respiratory specimens from 128 pediatric patients diagnosed with pneumonia in Beijing in late 2023. Mycoplasma pneumoniae was detected in 77.3% (99/128) patients, with 36.4% (4/11), 82.9% (34/41), 80.3% (61/76) in children aged less than 3 years, 3–6 years, over 7 years, respectively. Mycoplasma pneumoniae (M. pneumoniae) was characterized using P1 gene typing, MLVA typing and sequencing of domain V of the 23S rRNA gene. P1 gene type 1 (P1-1; 76.1%, 54/71) and MLVA type 4-5-7-2 (73.7%, 73/99) were predominant. MLVA identified a new genotype: 3–4–6-2. Macrolide resistance-associated mutations were detected in 100% of samples, with A2063G accounting for 99% and A2064G for 1%. The positive rate of M. pneumoniae was higher compared to previous reports, especially in children less than 3 years, suggesting a M. pneumoniae epidemic showing a younger age trend occurred in late 2023 in Beijing, China. Higher proportions of macrolide-resistant M. pneumoniae, P1-1 and 4-5-7-2 genotype M. pneumoniae indicated increased macrolide resistance rate and genotyping shift phenomenon, which might be attributable to this epidemic. Additionally, complete clinical information from 73 M. pneumoniae pneumonia inpatients were analyzed. The incidence of severe M. pneumoniae pneumonia was 56.2% (41/73). Mycoplasma pneumoniae pneumonia patients exhibited longer duration of fever, with a median value of 10.0 days (IQR, 8.0–13.0), and higher incidence of complications (74.0%, 54/73). However, in this cohort, we found that the severity of M. pneumoniae pneumonia, co-infection, or complications were not associated with M. pneumoniae P1 gene or MLVA types. Clinicians should be aware that patients infected with macrolide-resistant M. pneumoniae exhibited more severe clinical presentations.Keywords
This publication has 43 references indexed in Scilit:
- Current status of Mycoplasma pneumoniae infection in ChinaWorld Journal of Pediatrics, 2024
- What’s behind China’s mysterious wave of childhood pneumonia?Nature, 2023
- Mycoplasma pneumoniae: delayed re-emergence after COVID-19 pandemic restrictionsThe Lancet Microbe, 2023
- Molecular typing of Mycoplasma pneumoniae and its correlation with macrolide resistance in children in Henan of ChinaIndian Journal of Medical Microbiology, 2023
- Mycoplasma pneumoniae triggers pneumonia epidemic in autumn and winter in Beijing: a multicentre, population-based epidemiological study between 2015 and 2020Emerging Microbes & Infections, 2022
- Molecular and clinical characteristics of severe Mycoplasma pneumoniae pneumonia in childrenPediatric Pulmonology, 2019
- Mycoplasma pneumoniae in pediatric patients: Do macrolide-resistance and/or delayed treatment matter?Journal of Microbiology, Immunology and Infection, 2019
- Phylogenetic framework for the phylum Tenericutes based on genome sequence data: proposal for the creation of a new order Mycoplasmoidales ord. nov., containing two new families Mycoplasmoidaceae fam. nov. and Metamycoplasmataceae fam. nov. harbouring Eperythrozoon, Ureaplasma and five novel generaAntonie van Leeuwenhoek, 2018
- Severe macrolide-resistant Mycoplasma pneumoniae pneumonia associated with macrolide failureJournal of Microbiology, Immunology and Infection, 2016
- Culture-independent multi-locus variable-number tandem-repeat analysis (MLVA) of Mycoplasma pneumoniaeJournal of Microbiological Methods, 2011